Shopping Cart
- Remove All
Your shopping cart is currently empty
Ichorcumab (JNJ-375) is a fully human IgG4 antibody that targets thrombin. It binds to exosite 1 of thrombin, inhibiting substrate binding without affecting its catalytic activity. For isotype control, refer to HumanIgG1kappa, Isotype Control.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | Inquiry | Backorder | |
| 5 mg | Inquiry | Backorder |
| Description | Ichorcumab (JNJ-375) is a fully human IgG4 antibody that targets thrombin. It binds to exosite 1 of thrombin, inhibiting substrate binding without affecting its catalytic activity. For isotype control, refer to HumanIgG1kappa, Isotype Control. |
| In vitro | Ichorcumab (JNJ-9375) prolongs clotting time by binding to external site 1 on thrombin and inhibiting its interaction with fibrinogen and other substrates, such as factors V and VIII, as well as protease-activated receptor 1. As Ichorcumab does not affect thrombin's catalytic activity, it potentially causes less bleeding compared to anticoagulants blocking thrombin or factor Xa active sites [1]. |
| Synonyms | JNJ-9375, JNJ-64179375, JNJ-375, Ichorcumab |
| Cas No. | 2589583-20-8 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.